Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis Pharma leukemia drug gets US patent
The new patent covers the methods of using vosaroxin at clinically relevant dose ranges and schedules for leukemia treatment. Sunesis is now recruiting patients for Valor Phase 3
The new patent covers the methods of using vosaroxin at clinically relevant dose ranges and schedules for leukemia treatment. Sunesis is now recruiting patients for Valor Phase 3
Incyte has also received priority review status for ruxolitinib NDA, which the FDA aims to complete within six months. The NDA submission is supported by the results from
NPS Pharma has posted net loss of $6.13m, compared to $6.3m for the same period in the prior year. The company’s operating income was $4.04m for the second
Kadrige is engaged in forming a team of consultants, sales professionals, project managers and information technology engineers for marketing range of services with a plan to enable biopharma
Following the termination, the Nordic region’s distribution rights will again go back to Oasmia Pharma. Oasmia Pharma has developed a water soluble formulation of Paclitaxel with the retinoid
The tie up allows the US based company to carry forward the clinical development, manufacturing and commercialization of VR315 product. Vectura will provide support for the US development
The 505(b)(2) filing of NDA was supported by the results from a Phase 3 Freedom-301 clinical trial and an open-label, safety extension which was intended to investigate overall
Cephalon‘s net income was $115.19m, compared to $92.39m for the same period in the prior year. The company’s income from operations was $148.39m for the second quarter ended
Under the new deal, NPS will be responsible for filing applications for two of GSK’s experimental calcilytic compounds, SB-423557 and SB-423562 (NPSP790 and NPSP795). The new agreement will
CPI-300, a novel antidepressant, with a high strength of bupropion hydrochloride (HCl), is the active ingredient in Wellbutrin XL. Pillar5 has responded to all queries from the FDA